Trial
NCT03610490
Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
M.D. Anderson Cancer Center
Collaborators
Bristol-Myers Squibb; Iovance Biotherapeutics; National Cancer Institute (NCI)
Condition
Malignant Solid Neoplasm
Intervention
Autologous Tumor Infiltrating Lymphocytes MDA-TIL
Why stopped
Lack of Efficacy
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-04-17